Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus

Aliya A. Khan, Archie Morrison, David A. Hanley, Dieter Felsenberg, Laurie K. McCauley, Felice O'Ryan, Ian R. Reid, Salvatore L. Ruggiero, Akira Taguchi, Sotirios Tetradis, Nelson B. Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M. Cheung, Suzanne N. Morin, Basel Masri, Cyrus Cooper, Sarah L. MorganBarbara Obermayer-Pietsch, Bente L. Langdahl, Rana Al Dabagh, K. Shawn Davison, David L. Kendler, George K. Sándor, Robert G. Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D. Pierroz, Riad Sulimani, Deborah P. Saunders, Jacques P. Brown, Juliet Compston

Research output: Contribution to journalReview article

386 Citations (Scopus)

Abstract

This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1% to 15%), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001% to 0.01%, marginally higher than the incidence in the general population (<0.001%). New insights into the pathophysiology of ONJ include antiresorptive effects of BPs and Dmab, effects of BPs on gamma delta T-cells and on monocyte and macrophage function, as well as the role of local bacterial infection, inflammation, and necrosis. Advances in imaging include the use of cone beam computerized tomography assessing cortical and cancellous architecture with lower radiation exposure, magnetic resonance imaging, bone scanning, and positron emission tomography, although plain films often suffice. Other risk factors for ONJ include glucocorticoid use, maxillary or mandibular bone surgery, poor oral hygiene, chronic inflammation, diabetes mellitus, illfitting dentures, as well as other drugs, including antiangiogenic agents. Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those patients at high risk for the development of ONJ, including cancer patients receiving high-dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage. Management of ONJ is based on the stage of the disease, size of the lesions, and the presence of contributing drug therapy and comorbidity. Conservative therapy includes topical antibiotic oral rinses and systemic antibiotic therapy. Localized surgical debridement is indicated in advanced nonresponsive disease and has been successful. Early data have suggested enhanced osseous wound healing with teriparatide in those without contraindications for its use. Experimental therapy includes bone marrow stem cell intralesional transplantation, low-level laser therapy, local platelet-derived growth factor application, hyperbaric oxygen, and tissue grafting.

Original languageEnglish (US)
Pages (from-to)3-23
Number of pages21
JournalJournal of Bone and Mineral Research
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Osteonecrosis
Jaw
Oral Hygiene
Incidence
Diphosphonates
Jaw Neoplasms
Mouth Diseases
Teriparatide
Bone Density Conservation Agents
Population
Anti-Bacterial Agents
Inflammation
Therapeutics
Bone and Bones
Tissue Transplantation
Investigational Therapies
Cone-Beam Computed Tomography
Angiogenesis Inhibitors
Somatostatin-Secreting Cells
Oral Surgery

Keywords

  • Bisphosphonates
  • Denosumab
  • Diagnosis
  • Imaging
  • Management
  • Osteonecrosis of the jaw
  • Risk factors
  • Treatment

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., ... Compston, J. (2015). Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. Journal of Bone and Mineral Research, 30(1), 3-23. https://doi.org/10.1002/jbmr.2405

Diagnosis and management of osteonecrosis of the jaw : A systematic review and international consensus. / Khan, Aliya A.; Morrison, Archie; Hanley, David A.; Felsenberg, Dieter; McCauley, Laurie K.; O'Ryan, Felice; Reid, Ian R.; Ruggiero, Salvatore L.; Taguchi, Akira; Tetradis, Sotirios; Watts, Nelson B.; Brandi, Maria Luisa; Peters, Edmund; Guise, Teresa; Eastell, Richard; Cheung, Angela M.; Morin, Suzanne N.; Masri, Basel; Cooper, Cyrus; Morgan, Sarah L.; Obermayer-Pietsch, Barbara; Langdahl, Bente L.; Al Dabagh, Rana; Davison, K. Shawn; Kendler, David L.; Sándor, George K.; Josse, Robert G.; Bhandari, Mohit; El Rabbany, Mohamed; Pierroz, Dominique D.; Sulimani, Riad; Saunders, Deborah P.; Brown, Jacques P.; Compston, Juliet.

In: Journal of Bone and Mineral Research, Vol. 30, No. 1, 01.01.2015, p. 3-23.

Research output: Contribution to journalReview article

Khan, AA, Morrison, A, Hanley, DA, Felsenberg, D, McCauley, LK, O'Ryan, F, Reid, IR, Ruggiero, SL, Taguchi, A, Tetradis, S, Watts, NB, Brandi, ML, Peters, E, Guise, T, Eastell, R, Cheung, AM, Morin, SN, Masri, B, Cooper, C, Morgan, SL, Obermayer-Pietsch, B, Langdahl, BL, Al Dabagh, R, Davison, KS, Kendler, DL, Sándor, GK, Josse, RG, Bhandari, M, El Rabbany, M, Pierroz, DD, Sulimani, R, Saunders, DP, Brown, JP & Compston, J 2015, 'Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus', Journal of Bone and Mineral Research, vol. 30, no. 1, pp. 3-23. https://doi.org/10.1002/jbmr.2405
Khan, Aliya A. ; Morrison, Archie ; Hanley, David A. ; Felsenberg, Dieter ; McCauley, Laurie K. ; O'Ryan, Felice ; Reid, Ian R. ; Ruggiero, Salvatore L. ; Taguchi, Akira ; Tetradis, Sotirios ; Watts, Nelson B. ; Brandi, Maria Luisa ; Peters, Edmund ; Guise, Teresa ; Eastell, Richard ; Cheung, Angela M. ; Morin, Suzanne N. ; Masri, Basel ; Cooper, Cyrus ; Morgan, Sarah L. ; Obermayer-Pietsch, Barbara ; Langdahl, Bente L. ; Al Dabagh, Rana ; Davison, K. Shawn ; Kendler, David L. ; Sándor, George K. ; Josse, Robert G. ; Bhandari, Mohit ; El Rabbany, Mohamed ; Pierroz, Dominique D. ; Sulimani, Riad ; Saunders, Deborah P. ; Brown, Jacques P. ; Compston, Juliet. / Diagnosis and management of osteonecrosis of the jaw : A systematic review and international consensus. In: Journal of Bone and Mineral Research. 2015 ; Vol. 30, No. 1. pp. 3-23.
@article{a7acf427415245c4b78f6da1d29898cd,
title = "Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus",
abstract = "This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1{\%} to 15{\%}), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001{\%} to 0.01{\%}, marginally higher than the incidence in the general population (<0.001{\%}). New insights into the pathophysiology of ONJ include antiresorptive effects of BPs and Dmab, effects of BPs on gamma delta T-cells and on monocyte and macrophage function, as well as the role of local bacterial infection, inflammation, and necrosis. Advances in imaging include the use of cone beam computerized tomography assessing cortical and cancellous architecture with lower radiation exposure, magnetic resonance imaging, bone scanning, and positron emission tomography, although plain films often suffice. Other risk factors for ONJ include glucocorticoid use, maxillary or mandibular bone surgery, poor oral hygiene, chronic inflammation, diabetes mellitus, illfitting dentures, as well as other drugs, including antiangiogenic agents. Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those patients at high risk for the development of ONJ, including cancer patients receiving high-dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage. Management of ONJ is based on the stage of the disease, size of the lesions, and the presence of contributing drug therapy and comorbidity. Conservative therapy includes topical antibiotic oral rinses and systemic antibiotic therapy. Localized surgical debridement is indicated in advanced nonresponsive disease and has been successful. Early data have suggested enhanced osseous wound healing with teriparatide in those without contraindications for its use. Experimental therapy includes bone marrow stem cell intralesional transplantation, low-level laser therapy, local platelet-derived growth factor application, hyperbaric oxygen, and tissue grafting.",
keywords = "Bisphosphonates, Denosumab, Diagnosis, Imaging, Management, Osteonecrosis of the jaw, Risk factors, Treatment",
author = "Khan, {Aliya A.} and Archie Morrison and Hanley, {David A.} and Dieter Felsenberg and McCauley, {Laurie K.} and Felice O'Ryan and Reid, {Ian R.} and Ruggiero, {Salvatore L.} and Akira Taguchi and Sotirios Tetradis and Watts, {Nelson B.} and Brandi, {Maria Luisa} and Edmund Peters and Teresa Guise and Richard Eastell and Cheung, {Angela M.} and Morin, {Suzanne N.} and Basel Masri and Cyrus Cooper and Morgan, {Sarah L.} and Barbara Obermayer-Pietsch and Langdahl, {Bente L.} and {Al Dabagh}, Rana and Davison, {K. Shawn} and Kendler, {David L.} and S{\'a}ndor, {George K.} and Josse, {Robert G.} and Mohit Bhandari and {El Rabbany}, Mohamed and Pierroz, {Dominique D.} and Riad Sulimani and Saunders, {Deborah P.} and Brown, {Jacques P.} and Juliet Compston",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/jbmr.2405",
language = "English (US)",
volume = "30",
pages = "3--23",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of osteonecrosis of the jaw

T2 - A systematic review and international consensus

AU - Khan, Aliya A.

AU - Morrison, Archie

AU - Hanley, David A.

AU - Felsenberg, Dieter

AU - McCauley, Laurie K.

AU - O'Ryan, Felice

AU - Reid, Ian R.

AU - Ruggiero, Salvatore L.

AU - Taguchi, Akira

AU - Tetradis, Sotirios

AU - Watts, Nelson B.

AU - Brandi, Maria Luisa

AU - Peters, Edmund

AU - Guise, Teresa

AU - Eastell, Richard

AU - Cheung, Angela M.

AU - Morin, Suzanne N.

AU - Masri, Basel

AU - Cooper, Cyrus

AU - Morgan, Sarah L.

AU - Obermayer-Pietsch, Barbara

AU - Langdahl, Bente L.

AU - Al Dabagh, Rana

AU - Davison, K. Shawn

AU - Kendler, David L.

AU - Sándor, George K.

AU - Josse, Robert G.

AU - Bhandari, Mohit

AU - El Rabbany, Mohamed

AU - Pierroz, Dominique D.

AU - Sulimani, Riad

AU - Saunders, Deborah P.

AU - Brown, Jacques P.

AU - Compston, Juliet

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1% to 15%), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001% to 0.01%, marginally higher than the incidence in the general population (<0.001%). New insights into the pathophysiology of ONJ include antiresorptive effects of BPs and Dmab, effects of BPs on gamma delta T-cells and on monocyte and macrophage function, as well as the role of local bacterial infection, inflammation, and necrosis. Advances in imaging include the use of cone beam computerized tomography assessing cortical and cancellous architecture with lower radiation exposure, magnetic resonance imaging, bone scanning, and positron emission tomography, although plain films often suffice. Other risk factors for ONJ include glucocorticoid use, maxillary or mandibular bone surgery, poor oral hygiene, chronic inflammation, diabetes mellitus, illfitting dentures, as well as other drugs, including antiangiogenic agents. Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those patients at high risk for the development of ONJ, including cancer patients receiving high-dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage. Management of ONJ is based on the stage of the disease, size of the lesions, and the presence of contributing drug therapy and comorbidity. Conservative therapy includes topical antibiotic oral rinses and systemic antibiotic therapy. Localized surgical debridement is indicated in advanced nonresponsive disease and has been successful. Early data have suggested enhanced osseous wound healing with teriparatide in those without contraindications for its use. Experimental therapy includes bone marrow stem cell intralesional transplantation, low-level laser therapy, local platelet-derived growth factor application, hyperbaric oxygen, and tissue grafting.

AB - This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1% to 15%), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001% to 0.01%, marginally higher than the incidence in the general population (<0.001%). New insights into the pathophysiology of ONJ include antiresorptive effects of BPs and Dmab, effects of BPs on gamma delta T-cells and on monocyte and macrophage function, as well as the role of local bacterial infection, inflammation, and necrosis. Advances in imaging include the use of cone beam computerized tomography assessing cortical and cancellous architecture with lower radiation exposure, magnetic resonance imaging, bone scanning, and positron emission tomography, although plain films often suffice. Other risk factors for ONJ include glucocorticoid use, maxillary or mandibular bone surgery, poor oral hygiene, chronic inflammation, diabetes mellitus, illfitting dentures, as well as other drugs, including antiangiogenic agents. Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those patients at high risk for the development of ONJ, including cancer patients receiving high-dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage. Management of ONJ is based on the stage of the disease, size of the lesions, and the presence of contributing drug therapy and comorbidity. Conservative therapy includes topical antibiotic oral rinses and systemic antibiotic therapy. Localized surgical debridement is indicated in advanced nonresponsive disease and has been successful. Early data have suggested enhanced osseous wound healing with teriparatide in those without contraindications for its use. Experimental therapy includes bone marrow stem cell intralesional transplantation, low-level laser therapy, local platelet-derived growth factor application, hyperbaric oxygen, and tissue grafting.

KW - Bisphosphonates

KW - Denosumab

KW - Diagnosis

KW - Imaging

KW - Management

KW - Osteonecrosis of the jaw

KW - Risk factors

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84919934170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919934170&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2405

DO - 10.1002/jbmr.2405

M3 - Review article

C2 - 25414052

AN - SCOPUS:84919934170

VL - 30

SP - 3

EP - 23

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 1

ER -